Literature DB >> 21396901

Timing of serotype 1 pneumococcal disease suggests the need for evaluation of a booster dose.

K P Klugman1, S A Madhi, R A Adegbola, F Cutts, B Greenwood, W P Hausdorff.   

Abstract

Protection against serotype 1 could not be demonstrated in two randomized trials of 9 valent pneumococcal conjugate vaccines. An analysis of the timing of type 1 cases among vaccinees and controls shows that the vaccine failures occurred among cases occurring after the first year of life. Vaccination was given as three doses in infancy with no booster dose. These data suggest that a booster dose given at 9 months of age, or early in the second year of life, should be evaluated for protection against type 1 pneumococcal disease.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21396901     DOI： 10.1016/j.vaccine.2011.02.089

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  16 in total

Review 1.  The potential impact of pneumococcal conjugate vaccine in Africa: Considerations and early lessons learned from the South African experience.

Authors:  Shabir A Madhi; Marta C Nunes
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

2.  Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antiretroviral therapy.

Authors:  Mark J Abzug; Lin Ye Song; Myron J Levin; Sharon A Nachman; William Borkowsky; Stephen I Pelton
Journal:  Vaccine       Date:  2013-08-14       Impact factor: 3.641

3.  Serotype 5 pneumococci causing invasive pneumococcal disease outbreaks in Barcelona, Spain (1997 to 2011).

Authors:  Dora Rolo; Asunción Fenoll; Dionísia Fontanals; Nieves Larrosa; Montserrat Giménez; Immaculada Grau; Román Pallarés; Josefina Liñares; Carmen Ardanuy
Journal:  J Clin Microbiol       Date:  2013-08-21       Impact factor: 5.948

4.  Randomized, open-label study of the impact of age on booster responses to the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in children in India.

Authors:  Sanjay Lalwani; Sukanta Chatterjee; Jugesh Chhatwal; Anna Simon; Sudheer Ravula; Nancy Francois; Shailesh Mehta; Ana Strezova; Dorota Borys
Journal:  Clin Vaccine Immunol       Date:  2014-07-09

Review 5.  Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makers.

Authors:  Cynthia G Whitney; David Goldblatt; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

Review 6.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children.

Authors:  Laura Conklin; Jennifer D Loo; Jennifer Kirk; Katherine E Fleming-Dutra; Maria Deloria Knoll; Daniel E Park; David Goldblatt; Katherine L O'Brien; Cynthia G Whitney
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

7.  Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.

Authors:  Alassane Dicko; Gaoussou Santara; Almahamoudou Mahamar; Youssoufa Sidibe; Amadou Barry; Yahia Dicko; Aminata Diallo; Amagana Dolo; Ogobara Doumbo; Fakrudeen Shafi; Nancy François; Ana Strezova; Dorota Borys; Lode Schuerman
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

8.  Novel Strategy To Protect against Influenza Virus-Induced Pneumococcal Disease without Interfering with Commensal Colonization.

Authors:  Christopher J Greene; Laura R Marks; John C Hu; Ryan Reddinger; Lorrie Mandell; Hazeline Roche-Hakansson; Natalie D King-Lyons; Terry D Connell; Anders P Hakansson
Journal:  Infect Immun       Date:  2016-05-24       Impact factor: 3.441

9.  Epidemiology of Serotype 1 Invasive Pneumococcal Disease, South Africa, 2003-2013.

Authors:  Claire von Mollendorf; Cheryl Cohen; Stefano Tempia; Susan Meiring; Linda de Gouveia; Vanessa Quan; Sarona Lengana; Alan Karstaedt; Halima Dawood; Sharona Seetharam; Ruth Lekalakala; Shabir A Madhi; Keith P Klugman; Anne von Gottberg
Journal:  Emerg Infect Dis       Date:  2016-02       Impact factor: 6.883

10.  Impact of 13-Valent Pneumococcal Conjugate Vaccine on Pneumococcal Meningitis, Burkina Faso, 2016-2017.

Authors:  Heidi M Soeters; Dinanibè Kambiré; Guetawendé Sawadogo; Rasmata Ouédraogo-Traoré; Brice Bicaba; Isaïe Medah; Lassana Sangaré; Abdoul-Salam Ouédraogo; Soumeya Ouangraoua; Issaka Yaméogo; Malika Congo-Ouédraogo; Absatou Ky Ba; Flavien Aké; Velusamy Srinivasan; Ryan T Novak; Lesley McGee; Cynthia G Whitney; Chris Van Beneden
Journal:  J Infect Dis       Date:  2019-10-31       Impact factor: 5.226
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.